Table 3.
Variable | Serum 25(OH) D ng/ml Median(IQR) | p-value | Univariate Odds ratio (95%CI) | Multivariate Odds ratio (95%CI) |
---|---|---|---|---|
Gender | 0.91(0.49–1.62) | |||
Male | 20.65 (15.0–30.3) | 0.013 | Referent | |
Female | 23.3 (17.9–32.4) | 0.84 (0.49–1.42) | ||
Age | 1.32(0.40–2.09) | |||
≤ 50 years | 18.91 (15.6–27.5) | 0.142 | Referent | |
> 50 years | 22.63 (16.6–32.9) | 1.42 (0.7–2.9) | ||
CD4 Count | 0.36 (0.11–1.17) | |||
< 200/μL | 22.65 (16.6–32.9) | 0.127 | 0.69 (0.4–1.3) | |
≥ 200 | 19.98 (15.6–28.8) | Referent | ||
BMI | 0.61(0.27–1.38) | |||
≤ 18.5 | 22.27 (16.6–33.6) | 0.643 | 0.84 (0.5–1.5) | |
> 18.5 | 21.98 (16.4–30.9) | Referent | ||
EFV-Based Regimen | 0.87(0.32–2.34) | |||
Yes | 20.50 (15.1–33.1) | 0.664 | Referent | |
No | 21.81 (16.6–30.9) | 0.97 (0.4–2.3) | ||
cART status | 0.90(0.49–1.62) | |||
Yes | 20.84 (15.6–33.0) | 0.244 | Referent | |
No | 22.97 (16.9–30.6) | 1.04 (0.6–1.8) |
Key: IQR interquartile range, CI confidence interval, BMI Body Mass Index, EFV efavirenz, cART combination antiretroviral therapy. p-values of ≤ 0.05 were considered statistically significant